Abstract
Benzodiazepines are World Health Organisation essential medicines used in the treatment of alcohol withdrawal, anaesthesia, sedation, anxiolysis, behavioural disturbance, epilepsy, insomnia, palliative care, and muscle spasm. Despite their widespread use concerns remain over their long-term safety through both neuronal and non-neuronal effects. We conducted a systematic review to identify vulnerable populations of patients who may be at increased risk of harm from benzodiazepines. We identified three potentially “at risk” groups of patients, those with renal disease, lung disease and those recently hospitalised. However methodological limitations including selection bias, vague descriptors of benzodiazepine use and inappropriate grouping together of benzodiazepines with other medications, precluded definitive conclusions. Future studies should concentrate on these groups to identify the long-term safety of benzodiazepines in these patient groups.
Keywords: Benzodiazepine, mortality, infection, renal failure, dialysis, pneumonia, delirium, anxiolysis, anxiolysis, behavioural disturbance, epilepsy, insomnia, palliative care, muscle spasm, prognosis, anaesthesia, sedation
Current Drug Safety
Title:Long-Term Benzodiazepine Use and Mortality: Are we Doing the Right Studies?
Volume: 7 Issue: 5
Author(s): Umesh Kalum Amarasuriya, Puja R. Myles and Robert David Sanders
Affiliation:
Keywords: Benzodiazepine, mortality, infection, renal failure, dialysis, pneumonia, delirium, anxiolysis, anxiolysis, behavioural disturbance, epilepsy, insomnia, palliative care, muscle spasm, prognosis, anaesthesia, sedation
Abstract: Benzodiazepines are World Health Organisation essential medicines used in the treatment of alcohol withdrawal, anaesthesia, sedation, anxiolysis, behavioural disturbance, epilepsy, insomnia, palliative care, and muscle spasm. Despite their widespread use concerns remain over their long-term safety through both neuronal and non-neuronal effects. We conducted a systematic review to identify vulnerable populations of patients who may be at increased risk of harm from benzodiazepines. We identified three potentially “at risk” groups of patients, those with renal disease, lung disease and those recently hospitalised. However methodological limitations including selection bias, vague descriptors of benzodiazepine use and inappropriate grouping together of benzodiazepines with other medications, precluded definitive conclusions. Future studies should concentrate on these groups to identify the long-term safety of benzodiazepines in these patient groups.
Export Options
About this article
Cite this article as:
Kalum Amarasuriya Umesh, R. Myles Puja and David Sanders Robert, Long-Term Benzodiazepine Use and Mortality: Are we Doing the Right Studies?, Current Drug Safety 2012; 7 (5) . https://dx.doi.org/10.2174/1574886311207050007
DOI https://dx.doi.org/10.2174/1574886311207050007 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Molecular Therapeutics of HBV
Current Gene Therapy Development, Recent Achievements and Current Directions of Research into GABA Uptake Inhibitors
Current Medicinal Chemistry Drug Treatment of Obesity: Established and Emerging Therapies
Mini-Reviews in Medicinal Chemistry Synthesis and Evaluation of the Anticonvulsant Activities of New 5-substitued-[1,2,4]triazolo[4,3-a]quinoxalin-4(5H)-one Derivatives
Letters in Drug Design & Discovery The Mechanism of Action of Salsolinol in Brain: Implications in Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets Natural Products as a Source of CNS-Active Agents
Mini-Reviews in Organic Chemistry Neurosteroids and Sporadic Alzheimers Disease
Current Alzheimer Research CNS Drug Delivery Systems: Novel Approaches
Recent Patents on Drug Delivery & Formulation Phenytoin Induced Chorea: A Rare Adverse Effect of the Drug
Current Drug Safety Design, Synthesis and Biological Evaluation of Benzimidazole-pyridine- Piperidine Hybrids as a New Class of Potent Antimicrobial Agents
Letters in Drug Design & Discovery Driving Cellular Plasticity and Survival Through the Signal Transduction Pathways of Metabotropic Glutamate Receptors
Current Neurovascular Research Clozapine Safety, 40 Years Later
Current Drug Safety Neurocognitive Functioning and Cannabis Use in Schizophrenia
Current Pharmaceutical Design In Vivo MRI in Different Models of Experimental Epilepsy
Current Drug Targets Gene Therapy for Ischemic Brain Diseases
Current Gene Therapy Gastrin-Releasing Peptide Receptor as a Molecular Target for Psychiatric and Neurological Disorders
CNS & Neurological Disorders - Drug Targets The Medicinal Chemistry of 5-HT6 Receptor Ligands with a Focus on Arylsulfonyltryptamine Analogs
Current Topics in Medicinal Chemistry Proteins Structures in Leishmania Amastigotes for Clinical Remission of Psoriasis
Current Proteomics Catatonia: A Narrative Review
Central Nervous System Agents in Medicinal Chemistry Exosomes: Natural Carriers for siRNA Delivery
Current Pharmaceutical Design